Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01650805
Recruitment Status : Terminated (Study terminated based on evaluation of safety data.)
First Posted : July 26, 2012
Results First Posted : October 21, 2014
Last Update Posted : November 17, 2014
Information provided by (Responsible Party):
Ariad Pharmaceuticals

Brief Summary:
The purpose of this study is to compare the efficacy of ponatinib and imatinib in patients with newly diagnosed chronic myeloid leukemia (CML) in the chronic phase.

Condition or disease Intervention/treatment Phase
Chronic Myeloid Leukemia Drug: ponatinib Drug: imatinib (Gleevec/ Glivec) Phase 3

Expanded Access : An investigational treatment associated with this study has been approved for sale to the public.   More info ...

Detailed Description:

This multicenter, international, phase 3 trial will test the hypothesis that ponatinib is an effective treatment for newly diagnosed CP-CML patients when compared with standard imatinib.

Patients will be randomized in a 1:1 fashion, stratified by Sokal risk score at diagnosis (low, intermediate, high), to receive once daily oral administration of either ponatinib or imatinib. Efficacy measures include molecular, cytogenetic, and hematologic response rates at various timepoints; time to, duration of, and durability of responses; and survival follow-up. Safety measures include clinical laboratory testing, adverse event monitoring, vital signs, physical exams, ECGs, and ECHOs. Other measures include two patient-reported health outcomes questionnaires (FACT-Leu and EQ-5D-5L), determination of mutation status, and, for ponatinib only, measurement of steady-state plasma concentration. Accrual is expected to take approximately 2 years, and patients will be followed for survival for up to 8 years after the last patient's first dose; therefore, patient participation may last up to 10 years.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 307 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3 Randomized,Open-Label Study of Ponatinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Study Start Date : June 2012
Actual Primary Completion Date : October 2013
Actual Study Completion Date : October 2013

Arm Intervention/treatment
Experimental: ponatinib Drug: ponatinib
45 mg tablet, taken orally once daily

Active Comparator: imatinib Drug: imatinib (Gleevec/ Glivec)
400 mg tablet, taken orally once daily

Primary Outcome Measures :
  1. Major Molecular Response (MMR) Rate at 12 Months [ Time Frame: 12 months after first dose ]
    A ratio of reverse transcribed transcript of BCR-ABL to ABL ≤ 0.1% on the international scale, measured by real-time quantitative polymerase chain reaction.

Secondary Outcome Measures :
  1. MMR Rate [ Time Frame: 5 years after first dose ]
    To compare the efficacy of ponatinib with imatinib, as measured by MMR rate, at 5 years

  2. <10% BCR-ABL^IS Rate [ Time Frame: 3 months after first dose ]
    To compare the proportion of patients achieving a ratio of <10% BCR-ABL to ABL transcript levels at 3 months, as measured by the international scale (<10% BCR-ABL^IS), in patients administered ponatinib versus those administered imatinib

  3. Complete Cytogenetic Response (CCyR) Rate [ Time Frame: 12 months after first dose ]
    The percentage of Ph+ metaphases in bone marrow (peripheral blood may not be used), with a review of a minimum of 20 metaphases. Responses are defined as follows: Complete (CCyR): 0% Ph+ metaphases.

  4. Progression-free Survival [ Time Frame: Up to 8 years after the last patient's first dose ]
    To compare, according to treatment with ponatinib versus imatinib, progression-free survival

  5. Overall Survival [ Time Frame: Up to 8 years after the last patient's first dose ]
    To compare, according to treatment with ponatinib versus imatinib, overall survival

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. CP CML within 6 months of diagnosis

    • CP-CML will be defined by (i) <15% blasts in bone marrow; (ii) <30% blasts plus promyelocytes in bone marrow; (iii) <20% basophils in peripheral blood; (iv) ≥100 × 10^9/L platelets (≥100,000/mm^3); (v) No evidence of extramedullary disease except hepatosplenomegaly; AND (vi) No prior diagnosis of AP-CML or BP-CML
  2. Cytogenetic assessment must demonstrate the BCR-ABL fusion by presence of the t(9;22) Philadelphia chromosome

    • (a)Variant translocations are only allowed provided they are assessable for cytogenetic response utilizing conventional cytogenetic techniques; (b) Conventional chromosome banding must be performed; AND (c) A minimum of 20 metaphases must be assessable at entry
  3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
  4. Adequate hepatic function as defined by the following criteria:

    (a) Total serum bilirubin ≤1.5 x upper limit of normal (ULN), unless due to Gilbert's syndrome; (b) Alanine aminotransferase (ALT) ≤2.5 × ULN; AND (c) Aspartate aminotransferase (AST) ≤2.5 × ULN

  5. Adequate renal function as defined as defined by serum creatinine <1.5 x ULN
  6. Adequate pancreatic function as defined by serum lipase and amylase ≤1.5 × ULN

Exclusion Criteria:

  1. Received prior imatinib therapy
  2. Received prior dasatinib therapy
  3. Received prior nilotinib therapy
  4. Received, for CML, any other systemic anticancer therapy, experimental therapy, or radiation therapy with the exception of anagrelide or hydroxyurea
  5. Major surgery within 28 days prior to initiating therapy
  6. History of bleeding disorder unrelated to CML
  7. History of acute pancreatitis within 1 year of study or history of chronic pancreatitis
  8. History of alcohol abuse
  9. Have uncontrolled hypertriglyceridemia (triglycerides >450 mg/dL)
  10. Clinically significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:

    1. Myocardial infarction, within 6 months prior to randomization
    2. Unstable angina within 6 months prior to randomization
    3. Congestive heart failure within 6 months prior to randomization
    4. History of clinically significant (as determined by the treating physician) atrial arrhythmia or any ventricular arrhythmia
    5. Any history of ventricular arrhythmia
    6. Cerebrovascular accident or transient ischemic attack within 6 months prior to randomization
    7. Any history of peripheral arterial occlusive disease requiring revascularization
    8. Any history of venous thromboembolism including deep venous thrombosis or pulmonary embolism
  11. Uncontrolled hypertension (diastolic blood pressure >90 mm Hg; systolic >140 mm Hg). Patients with hypertension should be under treatment on study entry to effect blood pressure control
  12. Taking medications that are known to be associated with Torsades de Pointes
  13. Ongoing or active infection. The requirement for intravenous (IV) antibiotics is considered active infection
  14. Known history of human immunodeficiency virus (HIV). Testing is not required in the absence of history
  15. Pregnant or breastfeeding
  16. Malabsorption syndrome or other gastrointestinal illness that could affect oral absorption of study drugs
  17. Diagnosed with or received anticancer therapy for another primary malignancy within 3 years prior to entry (except for non-melanoma skin cancer or cervical cancer in situ)
  18. Any condition or illness that, in the opinion of the Investigator, would compromise patient safety or interfere with the evaluation of the drug

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01650805

  Hide Study Locations
United States, California
US Oncology - Providence Health System, Site #167
Burbank, California, United States, 91505
UCLA Department of Medicine, Site #027
Los Angeles, California, United States, 90095
Bay Area Cancer Research Group, Site #156
Pleasant Hill, California, United States, 94523
Bay Area Cancer Research Group, Site #157
Pleasant Hill, California, United States, 94523
United States, Colorado
Rocky Mountain Cancer Centers, Site #191
Boulder, Colorado, United States, 80303
United States, Connecticut
Cancer Center of Central Connecticut, Site #147
Southington, Connecticut, United States, 06489
United States, Delaware
Christiana Care Health Services, Site #155
Newark, Delaware, United States, 19713
United States, Florida
University Cancer Institute, Site #149
Boynton Beach, Florida, United States, 33426
Florida Cancer Specialists, Site #180
Fort Meyers, Florida, United States, 33916
Florida Cancer Specialists, Site #179
St. Petersburg, Florida, United States, 33705
United States, Georgia
Emory University, Site #058
Atlanta, Georgia, United States, 30322
United States, Illinois
John H. Stroger, Jr. Hospital of Cook County, Site #192
Chicago, Illinois, United States, 60612
University of Chicago, Site #001
Chicago, Illinois, United States, 60637
Loyola University Chicago, Site #054
Maywood, Illinois, United States, 60153
United States, Indiana
Franciscan St. Francis Health, Site #138
Indianapolis, Indiana, United States, 46237
United States, Iowa
University of Iowa Hospitals and Clinics, Site #050
Iowa City, Iowa, United States, 52242
Siouxland Hematology-Oncology Associates, Site #198
Sioux City, Iowa, United States, 51101
United States, Kansas
US Oncology - Cancer Center of Kansas, Site #168
Wichita, Kansas, United States, 67214
United States, Louisiana
Willis-Knighton Cancer Center, Site #196
Shreveport, Louisiana, United States, 71103
United States, Maryland
University of Maryland, Greenebaum Cancer Center, Site #040
Baltimore, Maryland, United States, 21201
Greater Baltimore Medical Center, Site #140
Baltimore, Maryland, United States, 21204
St. Agnes Healthcare, Site #185
Baltimore, Maryland, United States, 21229
United States, Massachusetts
Massachusetts General Hospital, Site #047
Boston, Massachusetts, United States, 02114
Dana Farber Cancer Institute, Site #008
Boston, Massachusetts, United States, 02215
University of Massachusetts Worcester, Site #152
Worcester, Massachusetts, United States, 01655
United States, Michigan
University of Michigan Medical Center, Site #011
Ann Arbor, Michigan, United States, 48109
Providence Cancer Institute, Site #197
Southfield, Michigan, United States, 48075
United States, Minnesota
Mayo Clinic, Site #044
Rochester, Minnesota, United States, 55905
Oncology Research Park Nicollet Institute, Site #195
St. Louis Park, Minnesota, United States, 55426
United States, Missouri
Saint Luke's Hospital, Site #162
Kansas City, Missouri, United States, 64111
Mercy Clinic - Cancer & Hematology, Site #151
Springfield, Missouri, United States, 65804
United States, Nebraska
Nebraska Hematology-Oncology, P.C., Site # 133
Lincoln, Nebraska, United States, 68506
United States, Nevada
US Oncology - Comprehensive Cancer Center of Nevada, Site #169
Las Vegas, Nevada, United States, 89169
United States, New Jersey
John Theurer Cancer Center, Site #128
Hackensack, New Jersey, United States, 07601
United States, New Mexico
University of New Mexico Cancer Center, Site #166
Albuquerque, New Mexico, United States, 87106
United States, New York
Maimonides Cancer Center, Site #177
Brooklyn, New York, United States, 11220
Winthrop University Hospital, Site #153
Mineola, New York, United States, 11501
Beth Israel Medical Center, Site #145
New York, New York, United States, 10003
Mount Sinai School of Medicine, Site #189
New York, New York, United States, 10029
Memorial Sloan-Kettering Cancer Center, Site #078
New York, New York, United States, 10065
Weill Cornell Medical College, Site #006
New York, New York, United States, 10065
New York Medical College, Site #146
Valhalla, New York, United States, 10595
United States, North Carolina
Southeastern Medical Oncology Center, Site #188
Goldsboro, North Carolina, United States, 27534
United States, Ohio
Signal Point Clinical Research Center, Site #139
Middletown, Ohio, United States, 45042
United States, Oklahoma
University of Oklahoma, Site #028
Oklahoma City, Oklahoma, United States, 73104
United States, Oregon
Providence Cancer Center Oncology and Hematology Care Eastside, Site #194
Portland, Oregon, United States, 97213
Kaiser Permanente Northwest, Site #200
Portland, Oregon, United States, 97227
Oregon Health & Science University, Site #048
Portland, Oregon, United States, 97239
United States, Pennsylvania
Gettysburg Cancer Center, Site #160
Gettysburg, Pennsylvania, United States, 17325
Western Pennsylvania Hospital, Site #159
Pittsburgh, Pennsylvania, United States, 15224
United States, South Carolina
Medical University of South Carolina, Site #148
Charleston, South Carolina, United States, 29425
Carolina Hematology Oncology, Site #143
Sumter, South Carolina, United States, 29150
United States, Tennessee
Associates in Oncology & Hematology, Site #186
Chattanooga, Tennessee, United States, 37421
Sarah Cannon Research Institute, Site #076
Nashville, Tennessee, United States, 37203
United States, Texas
US Oncology - Texas Oncology Austin, Site #172
Austin, Texas, United States, 78705
US Oncology - Texas Oncology Dallas, Site #171
Dallas, Texas, United States, 75231
University of Texas Southwestern Medical Center, Site #178
Dallas, Texas, United States, 75390
Baylor College of Medicine, Site #063
Houston, Texas, United States, 77030
US Oncology - Texas Oncology Midland, Site #173
Midland, Texas, United States, 79701
US Oncology - Cancer Care Center of South Texas, Site #170
San Antonio, Texas, United States, 78229
United States, Utah
Huntsman Cancer Institute, Site #043
Salt Lake City, Utah, United States, 84112
United States, Virginia
VCU Massey Cancer Center, Dalton Oncology Clinic, Site #069
Richmond, Virginia, United States, 23298
United States, Washington
Seattle Cancer Care Alliance, Site #100
Seattle, Washington, United States, 98109
US Oncology - Northwest Cancer Specialists, Site #174
Vancouver, Washington, United States, 98684
United States, West Virginia
West Virginia University, Site #154
Morgantown, West Virginia, United States, 26506
United States, Wisconsin
Green Bay Oncology, Ltd. / St. Mary's Hospital Medical Center, Site #193
Green Bay, Wisconsin, United States, 54303
University of Wisconsin, Site #030
Madison, Wisconsin, United States, 53792
Australia, Australian Capital Territory
Canberra Hospital, Site #971
Garran, Australian Capital Territory, Australia, 2605
Australia, New South Wales
Royal North Shore Hospital, Site #941
Sydney, New South Wales, Australia, 2065
Australia, South Australia
Royal Adelaide Hospital, Site #951
Adelaide, South Australia, Australia, 5000
Australia, Victoria
The Peter MacCallum Cancer Center, Site #950
East Melbourne, Victoria, Australia, 3002
Box Hill Hospital, Site #940
Melbourne, Victoria, Australia, 3128
Australia, Western Australia
Royal Perth Hospital, Site #972
Perth, Western Australia, Australia, 6000
Medizinische Universitat Wien / AKH, Universitatsklinik fur Inniere Medizin I, Site #561
Wien, Austria, 01090
UZ Brussel - Department Hematology, Site #544
Brussel, Belgium
Clinique Universitaire de Saint-Luc, Department of Haematology, Site #508
Bruxelles, Belgium, 3000
UZ Gent - Department Hematology, Site #756
Gent, Belgium
UZ Gasthuisberg - Department of Hematology, Site #700
Leuven, Belgium, 3000
Canada, Ontario
University Health Network, Princess Margaret Hospital, Site #083
Toronto, Ontario, Canada, M5G 2M9
Canada, Quebec
Jewish General Hospital, Site #129
Montreal, Quebec, Canada, H3T 1E2
Czech Republic
Fakultni nemocnice Brno, Interni hematologicka a onkologicka klinika, Site #514
Brno, Czech Republic, 62500
FN Hradec Kralove, Site #517
Hradec Kralove, Czech Republic, 50005
Fakultni nemocnice Olomouc, Hematoonkologicka klinika, Site #515
Olomouc, Czech Republic, 77520
Ustav hematologie a krevni transfuse, Site #516
Praha, Czech Republic, 12808
Helsinki University Central Hospital, Site #542
Helsinki, Finland
Institut Bergonie, Site #772
Bordeaux, France
CHRU de Brest, Hopital Morvan, Site #523
Brest, France, 29200
CHU Henri Mondor, Site #520
Creteil Cedex, France, 94010
Centre Hospitalier de Versailles, Site #958
Le Chesnay Cedex, France
Hospital Claude Huriez, Site #952
Lille Cedex, France, 59037
Institut Paoli Calmette, Site #519
Marseille, France
CHU de Brabois, Site #953
Nancy Cedex, France
CHU de Nantes, Site #521
Nantes Cedex, France, 44093
Service Hematologie - Hospital Archet I, Site #509
Nice Cedex, France, 06202
Hopital Saint-Louis, Site #957
Paris, France, 75475
Hospital Saint Antoine, Site #518
Paris, France
Centre Hospitalier Lyon Sud, Site #956
Pierre Benite, France, 69495
CHU de Poitiers, Site #954
Poitiers, France, 86021
CHU Purpan, Site #955
Toulouse Cedex, France
Universitätsklinikum Aachen, AÖR, Site #513
Aachen, Germany, 52074
Charite - Universitatsmedizin Berlin, Site #701
Berlin, Germany, 13353
Universitatsklinikum Carl Gustav Carus an der TU Dresden, Site #526
Dresden, Germany, 01307
Universitatsklinikum Freiburg, Site #527
Freiburg, Germany
Universitatsklinikum Hamburg-Eppendorf, Site #524
Hamburg, Germany, 20246
Universitatsklinikum Jena, Site #946
Jena, Germany, 07747
Universitatsklinikum Koln-AOR, Site #525
Koln, Germany, 50937
Universitat Heidelberg, CML - Studienzentrale III. Medizinische Klinik, Site #947
Mannheim, Germany, 68167
Klinikum rechts der Isar, Site #949
Munchen, Germany, 81675
Hong Kong
Prince of Wales Hospital, Site #974
Hong Kong, Hong Kong
Queen Mary Hospital, Site #973
Hong Kong, Hong Kong
Unita Operativa di Ematologia con Trapianto, Site #529
Bari, Italy, 70124
Istituto di Ematologia "L. & A. Seragnoli", Site #959
Bologna, Italy, 40138
A.O. Universitaria Policlinico Vittorio Emanuele di Catania, Site #530
Catania, Italy, 95124
Clinica Ematologica, Site #528
Genova, Italy, 16132
Ospedale Niguarda Ca' Granda di Milano, Site #531
Milan, Italy, 20162
S.C. Ematologia, Site #960
Modena, Italy, 41124
San Gerardo Hospital, Site #961
Monza, Italy, 20900
U.O.C Ematologia con trapianto di midollo osseo, Site #560
Napoli, Italy, 80131
Universita Federico II, Site #510
Napoli, Italy
SCDU Medicina Interna II - Indirizzo Ematologico, Site #785
Orbassano, Italy, 10043
Dipartimento di Biotecnologie Cellulari ed Ematologia Universita La Sapienza - Policlinico Umberto I, Site #511
Rome, Italy, 00161
U.O. di Ematologia - Ospedale S. Eugenio, Site #962
Rome, Italy, 144
Korea, Republic of
The Catholic University of Korea, Site #938
Seocho-gu, Seoul, Korea, Republic of, 137-701
VU Medical Centre - Department Haematology, Site #948
Amsterdam, Netherlands, 1081-HV
New Zealand
Auckland City Hospital, Site #921
Grafton, Auckland, New Zealand, 1023
Christchurch Hospital, Site #922
Christchurch, New Zealand
Waikato Hospital, Site #977
Hamilton, New Zealand
North Shore Hospital, Site #976
Takapuna, New Zealand, 0740
Klinika Hematologii i Transplantologii, Uniwersyteckie Centrum Medyczne, Site #548
Gdansk, Poland
Malopolskie Centrum Medyczne, Site #546
Krakow, Poland
Klinika Hematologii Wojewodzkiego Szpitala Specjalistycznego, Site #550
Lodz, Poland
Oddzial Hematologii, Site #551
Rzeszow, Poland, 35-055
Katedra i Klinika Hematologii, Site #547
Wroclaw, Poland
Instituto Portugues de Oncologia, Site #545
Lisboa, Portugal, 1099-023
Puerto Rico
Fundacion de Investigacion de Diego, Site #199
San Juan, Puerto Rico, 00927
Singapore General Hospital, Site #939
Singapore, Singapore
Narodny onkologicky ustav, Site #532
Bratislava, Slovakia, 833 10
Univerzitna nemocnica Martin, Site #533
Martin, Slovakia, 036 59
Complejo Hospitalario Universitario A Coruna, Hospital "Teresa Herrera," Site #554
A Coruna, Spain, 15006
Hospital Universitari Germans Trias i Pujol, Site #512
Badalona, Spain, 08916
Hospital Clinic, Site #963
Barcelona, Spain, 08036
Institut Catala d' Oncologia de Girona, S. de Hematologia Clinica, Site #734
Girona, Spain, 17007
Hospital Universitari Son Espases, Site #553
Islas Baleares, Spain, 07010
Hospital Universitario La Princesa, Site #555
Madrid, Spain, 28006
Hospital Gregorio Maranon, Site #536
Madrid, Spain, 28007
H.U. Ramon y Cajal, Site #538
Madrid, Spain, 28034
Hospital Universitario 12 de Octubre, Site #537
Madrid, Spain, 28041
Hospital La Paz, Site #966
Madrid, Spain, 28046
Hospital Universitario Central de Asturias, Site #535
Oviedo, Spain, 33006
Hospital Universitario de Salamanca, Site #965
Salamanca, Spain, 37007
Hospital Clinico Universitario de Valencia, Site #964
Valencia, Spain, 46010
Skane University Hospital, Site #944
Lund, Sweden
Karolinska University Hospital Huddinge, Site #534
Stockholm, Sweden
Karolinska University Hospital Solna, Site #763
Stockholm, Sweden
Uppsala University Hospital, Site #945
Uppsala, Sweden
Kantonsspital Aarau, Site #541
Aarau, Switzerland, 5001
Kantonsspital St. Gallen, Site #707
St Gallen, Switzerland, 9007
Kaohsiung Chang Gung Memorial Hospital, Site #980
Kaohsiung, Taiwan
China Medical University Hospital, Site #978
Taiching, Taiwan, 40447
National Taiwan University Hospital, Site #979
Taipei, Taiwan, 10002
United Kingdom
Western General Hospital, Site #556
Edinburgh, United Kingdom, EH4 2XU
Kent and Medway Cancer Research Network, Site #558
Gillingham, United Kingdom
University of Glasgow, Site #797
Glasgow, United Kingdom, G120SB
St. James University Hospital, Site #540
Leeds, United Kingdom, LS9 7TF
Royal Liverpool University Hospital, Site #969
Liverpool, United Kingdom, L7 8XP
Hammersmith Hospital, Site #967
London, United Kingdom
Newcastle University, Site #970
Newcastle, United Kingdom
Norfolk & Norwich University Hospital Foundation Trust, Site #557
Norwich, United Kingdom
Nottingham University Hospitals NHS Trust, Site #968
Nottingham, United Kingdom, NG5 1PB
Oxford University Hospitals NHS Trust, Site #543
Oxford, United Kingdom
Sponsors and Collaborators
Ariad Pharmaceuticals

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Ariad Pharmaceuticals Identifier: NCT01650805     History of Changes
Other Study ID Numbers: AP24534-12-301
First Posted: July 26, 2012    Key Record Dates
Results First Posted: October 21, 2014
Last Update Posted: November 17, 2014
Last Verified: October 2014

Keywords provided by Ariad Pharmaceuticals:
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases

Additional relevant MeSH terms:
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Neoplasms by Histologic Type
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action